Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9UQ07
UPID:
MOK_HUMAN
Alternative names:
MOK protein kinase; Renal tumor antigen 1
Alternative UPACC:
Q9UQ07; B2R6Z4; B7Z7P6; E7ER76; E7ERR8; Q92790; Q93067
Background:
MAPK/MAK/MRK overlapping kinase, also known as MOK protein kinase or Renal tumor antigen 1, is a pivotal enzyme capable of phosphorylating various substrates and executing autophosphorylation. It plays a crucial role in regulating cilium length through cAMP and mTORC1 signaling pathways.
Therapeutic significance:
Understanding the role of MAPK/MAK/MRK overlapping kinase could open doors to potential therapeutic strategies.